University of Rochester: Lymphoma trials

The registry lists 11 Lymphoma studies with University of Rochester as lead sponsor. 2 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 6Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S TrialRecruitingNCT05006482Phase 3
• Umbilical Cord Blood Transplantation From Unrelated DonorsRecruitingNCT03016806
• Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaCompletedNCT03788291Phase 2Results posted
• A Phase II Study of Doxycycline in Relapsed NHLTerminatedNCT02086591Phase 2Results posted
• Imexon for Relapsed Follicular and Aggressive LymphomasCompletedNCT01314014Phase 2Results posted
• Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaCompletedNCT00547534Phase 2Results posted
• Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00262860Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic CancerTerminatedNCT00255684Not applicableResults posted
• Study of Carfilzomib and Vorinostat for Relapsed or Refractory LymphomaCompletedNCT01276717Phase 1
• Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's LymphomaCompletedNCT00903890
• Rituximab Plus Interleukin-2 in Treating Patients With LymphomaCompletedNCT00003356Phase 1/2